Cocrystal Technology Fights Kaneka's Patent Infringement Lawsuit Over Crystal QH®

Cocrystal Technology's Legal Challenges with Kaneka Corporation



Cocrystal Technology Co., Ltd. has found itself at the center of a patent dispute filed in the United States District Court for the Eastern District of New York, with significant implications for its flagship product, Crystal QH®. The lawsuit, initiated by Kaneka Corporation under Case Number 123-cv-07483-APR-SJB, claims that Cocrystal's innovative coenzyme Q10 supplement infringes on U.S. Patent No. 7,829,080, known as the '080 Patent'.

Background on the Dispute


The accusations primarily revolve around Cocrystal's Crystal QH®, a premium formulation designed to enhance bioavailability and stability—key factors in the effectiveness of dietary supplements containing coenzyme Q10. Kaneka asserts that its patent provides exclusive rights over specific methods and compositions involving reduced coenzyme Q10, which it claims Cocrystal has violated.

Cocrystal has a different perspective and is currently disputing the validity of these patent claims. The company believes the claims lack the necessary qualities such as novelty and adequate disclosure, which are essential for patent protections. Furthermore, Cocrystal points out that one of the ingredients in question, reduced coenzyme Q11, is a naturally occurring impurity, emphasizing that it should not be subject to patent claims as stated in the '080 Patent.

Cocrystal's Commitment to Innovation


Cocrystal Technology prides itself on being a pioneer in drug cocrystal technology, harnessing innovative methods to improve the health and wellness arena. The firm not only aims to defend its right to produce Crystal QH® without infringement but also remains focused on developing active ingredients that offer improved stability and bioavailability across its range of nutritional solutions.

The solid scientific foundation supporting Cocrystal's claims has positioned them to successfully challenge Kaneka's assertions. Cocrystal argues that the claims against them fail to meet the rigorous standards for patentability, as already stipulated by various industry standards and academic research.

Furthermore, Cocrystal has stated emphatically that this legal dispute should not negatively impact its market performance or the availability of Crystal QH® in the United States and beyond. In the company's communication, they have reassured customers and partners that they are fully committed to safeguarding their interests while navigating the legal process.

Looking Ahead


As the case continues, Cocrystal’s management remains optimistic about the outcome. They are striving to ensure that their legitimate rights are upheld, allowing them to continue providing high-quality dietary supplements without legal encumbrances. This case not only highlights the fierce competition in the health supplement sector but also underscores the importance of patent validity when it comes to innovations in health products.

In summary, the dispute between Cocrystal Technology and Kaneka Corporation will likely unfold further, bringing to light important questions about patent law applicability in the fast-evolving nutritional solutions market. As the industry watches closely, the proceedings will have far-reaching consequences for both companies and potentially reshape future innovation paths in dietary supplements.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.